Foundation
Peregrion empowers drug innovators to accelerate clinical timelines
Traditionally, finding out exactly how a new drug asset transits and metabolizes inside the human body happens very late in the process.
Peregrion generates the insights in Phase 1. Early data on human absorption, metabolism and excretion of drugs provides pharma and biotech companies with the definitive, early-stage proof they need to refine and optimize continued development.
As a TNO spin-off rooted in 15+ years of research, Peregrion leverages proprietary Accelerator Mass Spectrometry (AMS) technology to enable ethical 14C-microtracer studies as early as Phase 1.
A foundation of scientific trust
Our capability is built on a strong scientific foundation. As a specialized spin-off from the renowned Dutch research organization TNO, Peregrion inherits more than a decade of pioneering research in AMS technology and trusted partnerships with global pharmaceutical leaders. Our operations are powered by a proprietary, automated auto-combustion AMS platform. This system delivers 500-fold greater sensitivity than conventional analytical methods by isolating and quantifying carbon-14 isotopes, yielding high-integrity data from microtracer doses.
Meet the founders
Wouter Vaes
Co-founder of Peregrion BV and founder of the earlier established TNO AMS laboratories. Wouter has a background in a analytical chemistry and holds a PhD in Toxicology. He has over 25 years experience in leading GxP, ISO17025 and ISO9001 accredited laboratories.
Steven Erpelinck
Co-founder of Peregrion BV. Steven has a background in Biotechnology (BSc) and holds an MBA in Sales & Marketing. He has over 20 years-experience in business development within the Life Science and Pharmaceutical Industry.
